MacroGenics, Inc. Overview
Pro stress-test →MacroGenics is a biotechnology company focused on discovering and developing antibody-based therapeutics for cancer treatment, with its approved product MARGENZA for metastatic HER2-positive breast cancer. The company maintains collaborations with TerSera Therapeutics, Incyte Corporation, and Gilead Sciences.
Strategic Profile
Pro stress-test →The company operates a pipeline of bispecific and antibody-drug conjugate candidates targeting tumor-associated antigens and immune checkpoint molecules, including lorigerlimab, MGC026, and MGC028. MacroGenics leverages proprietary Fc engineering and Dual Activating ReTargeting technology to improve antibody functions and eliminate cancer cells.
Competitive Landscape
Pro stress-test →Top competitors include Moderna, Jazz Pharmaceuticals, and BeiGene. MacroGenics operates in a crowded oncology immunotherapy space where multiple companies develop checkpoint inhibitors and antibody-drug conjugates. The company's focus on proprietary Fc engineering and DART technology differentiates it, though recent safety setbacks have weakened its competitive position.
Industry Context
MacroGenics, Inc. operates in Biopharmaceutical - Oncology/Immunotherapy.
Key facts
Founded: 2000 · Headquarters: Rockville, US · Employees: 391 · Revenue: $149.96M (2024) · Market cap: $126M